Clinical Trial Update: FHND9041 Versus Afatinib for Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing FHND9041 to Afatinib for non-small cell lung cancer is currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Afatinib (afatinib)
• FHND9041

Snippet

Sponsor: Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | Conditions: Non Small Cell Lung Cancer | Phase 3 | Status: ENROLLING_BY_INVITATION